temozolomide has been researched along with Adenoma in 70 studies
Adenoma: A benign epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas." | 8.90 | Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. ( Hirohata, T; Hoya, K; Ide, F; Ishii, Y; Matsuno, A; Miyamoto, S; Mizutani, A; Murakami, M; Nagashima, H; Nishido, H; Okinaga, H; Osamura, RY; Son, JH; Sugaya, M; Tahara, S; Teramoto, A; Yamada, S; Yamada, SM, 2014) |
| "Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas." | 8.88 | Temozolomide in aggressive pituitary adenomas and carcinomas. ( Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H, 2012) |
| "Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging." | 7.96 | Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. ( Bojunga, J; Buchfelder, M; Buslei, R; Deutschbein, T; Droste, M; Elbelt, U; Honegger, J; Johanssen, S; Knappe, UJ; Kolenda, H; Lammert, A; Micko, A; Petersenn, S; Ritzel, K; Schlaffer, SM; Strasburger, CJ; Topuzoglu-Müller, T; Unger, N; Vila, G, 2020) |
| "Crooke's cell adenoma (CCA) is an aggressive subtype of corticotroph adenoma; however, CCA is associated with a high incidence of low expression of methyl guanine methyl transferase (MGMT), suggesting that temozolomide (TMZ) treatment might be effective for this tumor type." | 7.91 | Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. ( Inoshita, N; Kanazawa, I; Kurosaki, M; Morita, M; Oki, Y; Sugimoto, T; Takeno, A; Tanaka, S; Yamada, S; Yamaguchi, T; Yamamoto, M, 2019) |
| "To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA)." | 7.91 | Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. ( Aharon-Hananel, G; Badarna, M; Percik, R; Tirosh, A; Uri, I, 2019) |
| "Pituitary adenomas usually develop temozolomide resistance, which could compromise the anticancer effects of temozolomide." | 7.83 | HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy. ( Bin, X; Bingbing, X; Dongchun, W; Kun, Z; Xiaoli, L; Yuling, Y, 2016) |
| "Temozolomide is effective in some patients with progressive pituitary adenoma or carcinoma." | 7.83 | Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. ( Bogazzi, F; Cannavo, S; Ceccato, F; Curtò, L; De Marinis, L; Iacovazzo, D; Lombardi, G; Losa, M; Mantovani, G; Mazza, E; Minniti, G; Nizzoli, M; Reni, M; Scaroni, C, 2016) |
| "Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas." | 7.83 | Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( Laterra, JJ; Salvatori, R; Strowd, RE, 2016) |
| "O6-methylguanine-DNA methyltransferase (MGMT) activity is responsible for temozolomide (TMZ) resistance in patients harboring aggressive pituitary adenomas." | 7.81 | Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression. ( Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y, 2015) |
| "Invasive pituitary adenomas (PAs) are often refractory to standard therapy and salvage treatment with temozolomide (TMZ)." | 7.79 | Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. ( Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H, 2013) |
| "Temozolomide treatment has a wide range of efficacy in patients with pituitary carcinoma or locally aggressive pituitary adenoma." | 7.76 | Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. ( Cangi, MG; Gill, AJ; Losa, M; Mazza, E; McCormack, A; Mortini, P; Motta, M; Reni, M; Talarico, A; Terreni, MR, 2010) |
| "Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary tumors." | 7.01 | Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. ( Barbot, M; Bergo, E; Caccese, M; Ceccato, F; Cerretti, G; Lombardi, G; Occhi, G; Padovan, M; Scaroni, C, 2023) |
| "Temozolomide (TMZ) was proposed as a treatment option for pituitary carcinomas and aggressive pituitary adenomas." | 6.74 | O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? ( Czech, T; Knosp, E; Kotter, MR; Marosi, C; Preusser, M; Widhalm, G; Woehrer, A; Wolfsberger, S, 2009) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 6.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "A significant proportion of pituitary adenomas and carcinomas had low MGMT immunoexpression." | 6.47 | Treatment of pituitary neoplasms with temozolomide: a review. ( Cusimano, M; Gonzalez, R; Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Ortiz, LD; Scheithauer, BW; Syro, LV; Uribe, H, 2011) |
| "Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal multimodality therapy." | 5.62 | Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. ( Ahuja, CK; Bhansali, A; Das, L; Dhandapani, S; Dutta, P; Gupta, K; Gupta, N; Radotra, BD; Rai, A; Sood, R; Sreedharanunni, S; Tripathi, M; Vaiphei, K; Walia, R, 2021) |
| "Pituitary adenomas are the commonest intracranial tumor, but metastases are rare (0." | 5.43 | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. ( Arnal, AV; Donovan, LE; Odia, Y; Wang, SH, 2016) |
| "Temozolomide (TMZ) is an oral alkylating drug with good tolerability, approved for treatment of malignant gliomas." | 5.42 | Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. ( Andersen, M; Bengtsson, D; Berinder, K; Burman, P; Feldt Rasmussen, U; Hoybye, C; Johannsson, G; Maiter, D; Petersson, M; Ragnarsson, O; Rasmussen, ÅK; Schrøder, HD; van der Lely, AJ, 2015) |
| "Aggressive pituitary adenomas (PAs) are clinically challenging for endocrinologists and neurosurgeons due to their locally invasive nature and resistance to standard treatment (surgery, medical or radiotherapy)." | 5.42 | Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. ( Bertorelle, R; Boscaro, M; Ceccato, F; D'Avella, D; Denaro, L; Emanuelli, E; Gardiman, MP; Lombardi, G; Manara, R; Milanese, L; Occhi, G; Scanarini, M; Scaroni, C; Zagonel, V, 2015) |
| "The established first-line medical therapy for refractory adenomas is temozolomide, which importantly may increase survival, but clinical trial data are still needed to clearly establish its efficacy, identify biomarkers of response, and clarify eligibility and outcome criteria." | 5.41 | Medical therapy for refractory pituitary adenomas. ( Geer, EB, 2023) |
| "Pituitary carcinoma is extremely rare and difficult to diagnose early." | 5.40 | Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management. ( Jiang, S; Yin, S; Zhong, C; Zhou, P, 2014) |
| "Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas." | 5.39 | DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. ( Amano, K; Arita, K; Asano, K; Fujio, S; Fukuhara, N; Hirohata, T; Hizuka, N; Ikeda, H; Ishii, Y; Isozaki, O; Iwai, Y; Kawamata, T; Matsuno, A; Nishioka, H; Ogawa, Y; Osamura, RY; Sakata, K; Shimatsu, A; Tahara, S; Takano, K; Takano, S; Teramoto, A; Tominaga, A; Yamada, S, 2013) |
| " Targeting dopamine and somatostatin receptors on corticotroph adenomas with cabergoline or pasireotide, or both, controls cortisol production in up to 40% of patients." | 5.01 | Advances in the medical treatment of Cushing's syndrome. ( Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R, 2019) |
| " More recently, temozolomide, a second generation oral alkylating agent, has shown therapeutic promise for aggressive pituitary adenomas and carcinomas with favorable clinical and radiographic responses." | 4.91 | The role of temozolomide in the treatment of aggressive pituitary tumors. ( Eloy, JA; Liu, JK; Patel, J, 2015) |
| "There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas." | 4.90 | Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. ( Hirohata, T; Hoya, K; Ide, F; Ishii, Y; Matsuno, A; Miyamoto, S; Mizutani, A; Murakami, M; Nagashima, H; Nishido, H; Okinaga, H; Osamura, RY; Son, JH; Sugaya, M; Tahara, S; Teramoto, A; Yamada, S; Yamada, SM, 2014) |
| "Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas." | 4.88 | Temozolomide in aggressive pituitary adenomas and carcinomas. ( Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H, 2012) |
| " Recent evidence suggests that temozolomide (TMZ), an orally-active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas." | 4.88 | Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. ( Annamalai, AK; Antoun, NM; Burnet, NG; Burton, H; Cheow, HK; Dean, AF; Gurnell, M; Halsall, DJ; Jefferies, SJ; Kandasamy, N; Kirollos, RW; Kovacs, K; Pickard, JD; Shaw, AS; Simpson, HL, 2012) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent that has recently been used in some cases as a new therapeutic tool for pituitary carcinomas and aggressive pituitary adenomas." | 4.86 | Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. ( Altavilla, G; Cannavò, S; Curtò, L; Ferraù, F; Granata, F; Hofland, LJ; Longo, M; Pitini, V; Torre, ML; Trimarchi, F, 2010) |
| "Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging." | 3.96 | Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. ( Bojunga, J; Buchfelder, M; Buslei, R; Deutschbein, T; Droste, M; Elbelt, U; Honegger, J; Johanssen, S; Knappe, UJ; Kolenda, H; Lammert, A; Micko, A; Petersenn, S; Ritzel, K; Schlaffer, SM; Strasburger, CJ; Topuzoglu-Müller, T; Unger, N; Vila, G, 2020) |
| "To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA)." | 3.91 | Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. ( Aharon-Hananel, G; Badarna, M; Percik, R; Tirosh, A; Uri, I, 2019) |
| "Crooke's cell adenoma (CCA) is an aggressive subtype of corticotroph adenoma; however, CCA is associated with a high incidence of low expression of methyl guanine methyl transferase (MGMT), suggesting that temozolomide (TMZ) treatment might be effective for this tumor type." | 3.91 | Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. ( Inoshita, N; Kanazawa, I; Kurosaki, M; Morita, M; Oki, Y; Sugimoto, T; Takeno, A; Tanaka, S; Yamada, S; Yamaguchi, T; Yamamoto, M, 2019) |
| "To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment." | 3.88 | Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. ( Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J, 2018) |
| "Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas." | 3.83 | Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( Laterra, JJ; Salvatori, R; Strowd, RE, 2016) |
| "Temozolomide is effective in some patients with progressive pituitary adenoma or carcinoma." | 3.83 | Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. ( Bogazzi, F; Cannavo, S; Ceccato, F; Curtò, L; De Marinis, L; Iacovazzo, D; Lombardi, G; Losa, M; Mantovani, G; Mazza, E; Minniti, G; Nizzoli, M; Reni, M; Scaroni, C, 2016) |
| "Pituitary adenomas usually develop temozolomide resistance, which could compromise the anticancer effects of temozolomide." | 3.83 | HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy. ( Bin, X; Bingbing, X; Dongchun, W; Kun, Z; Xiaoli, L; Yuling, Y, 2016) |
| "O6-methylguanine-DNA methyltransferase (MGMT) activity is responsible for temozolomide (TMZ) resistance in patients harboring aggressive pituitary adenomas." | 3.81 | Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression. ( Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y, 2015) |
| "To study the expression of D2R, MGMT and VEGF for clinical significance in pituitary adenomas, and to predict the potential curative medical therapy of dopamine agonists, temozolomide and bevacizumab on pituitary adenomas." | 3.80 | The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. ( Hu, Y; Li, J; Li, W; Lu, Z; Ma, C; Tohti, M; Wang, S; Wang, Y, 2014) |
| "Invasive pituitary adenomas (PAs) are often refractory to standard therapy and salvage treatment with temozolomide (TMZ)." | 3.79 | Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. ( Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H, 2013) |
| "Recent publications suggest the utility of temozolomide (TMZ) in the management of aggressive pituitary adenomas and carcinomas, resistant to conventional treatments." | 3.77 | MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. ( Altuntaş, Y; Çil, E; Karaman, Ö; Müslüman, AM; Özkayalar, H; Öztürk, FY; Tanik, C; Velet, S; Zuhur, SS, 2011) |
| "MGMT promoter hypermethylation of aggressive pituitary adenomas and pituitary carcinomas and low protein expression are implicated in improved response to treatment with temozolomide (TMZ)." | 3.77 | MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. ( Erickson, D; Fealey, M; Horvath, E; Kovacs, K; Kros, JM; Lau, Q; Lloyd, RV; Salehi, F; Scheithauer, BW, 2011) |
| "Temozolomide treatment has a wide range of efficacy in patients with pituitary carcinoma or locally aggressive pituitary adenoma." | 3.76 | Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. ( Cangi, MG; Gill, AJ; Losa, M; Mazza, E; McCormack, A; Mortini, P; Motta, M; Reni, M; Talarico, A; Terreni, MR, 2010) |
| "The objective of the study was to assess O(6)-methylguanine-DNA methyltransferase (MGMT) immunoreactivity in pituitary adenomas of silent subtype 3 as a potential indicator of temozolomide susceptibility." | 3.76 | MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. ( Erickson, D; Fealey, ME; Horvath, E; Kovacs, K; Lloyd, RV; McLendon, R; Scheithauer, BW, 2010) |
| "Three cases of patients with pituitary adenomas who underwent temozolomide treatment are presented." | 3.75 | Use of temozolomide in aggressive pituitary tumors: case report. ( Cusimano, MD; Kovacs, K; Mason, W; Mohammed, S; Smyth, H, 2009) |
| "Pituitary tumors are defined as refractory when resistance to optimal standard therapies including surgery, radiotherapy, and medical treatment is documented." | 3.01 | Refractory nonfunctioning pituitary adenomas. ( Greenman, Y; Kolitz, T, 2023) |
| "Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary tumors." | 3.01 | Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. ( Barbot, M; Bergo, E; Caccese, M; Ceccato, F; Cerretti, G; Lombardi, G; Occhi, G; Padovan, M; Scaroni, C, 2023) |
| "Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors (APTs) and carcinomas present important diagnostic and therapeutic challenges and are associated with a high mortality rate." | 2.82 | Aggressive corticotroph tumors and carcinomas. ( Ilie, MD; Jouanneau, E; Lasolle, H; Raverot, G; Vasiljevic, A, 2022) |
| "Although pituitary adenomas (PAs) account for 15% of intracranial tumors, pituitary carcinomas (PCs) are a rare entity." | 2.82 | Pituitary carcinoma - case series and review of the literature. ( Andreescu, CE; Bruneau, M; Du Four, S; Duerinck, J; Neyns, B; Van Der Veken, J; Velkeniers, B; Velthoven, V; Vermeulen, E, 2022) |
| "Temozolomide (TMZ) was proposed as a treatment option for pituitary carcinomas and aggressive pituitary adenomas." | 2.74 | O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? ( Czech, T; Knosp, E; Kotter, MR; Marosi, C; Preusser, M; Widhalm, G; Woehrer, A; Wolfsberger, S, 2009) |
| "Cushing's disease is a syndromic pathological condition caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by hypercortisolemia." | 2.72 | Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. ( Fukuoka, H; Nakao, T; Ogawa, W; Yamamoto, M, 2021) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 2.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "Non-functioning pituitary adenomas (NFPAs) are in general large tumors that present with symptoms secondary to local pressure on adjacent structures." | 2.58 | Management of NFAs: medical treatment. ( Even-Zohar, N; Greenman, Y, 2018) |
| "Aggressive pituitary tumours causing Cushing's Disease are very rare, difficult to treat, and usually resistant to conventional therapy." | 2.58 | Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review. ( Gilis-Januszewska, A; Hubalewska-Dydejczyk, A; Kluczyński, Ł; Pach, D; Pantofliński, J; Sokołowski, G; Sowa-Staszczak, A; Turek-Jabrocka, R; Wilusz, M; Zieliński, G, 2018) |
| "Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome." | 2.58 | Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). ( Lenders, N; McCormack, A, 2018) |
| "Temozolomide is an oral chemotherapy with a favorable side-effect profile that has shown activity against pituitary adenomas." | 2.53 | Is there a role for early chemotherapy in the management of pituitary adenomas? ( DeAngelis, LM; Lin, AL; Sum, MW, 2016) |
| "Aggressive pituitary adenomas, defined from a clinical perspective, have earlier and more frequent recurrences and can be resistant to conventional treatments." | 2.50 | Aggressive pituitary adenomas--diagnosis and emerging treatments. ( Cusimano, MD; Di Ieva, A; Kovacs, K; Rotondo, F; Syro, LV, 2014) |
| "Atypical pituitary adenomas (APAs) are aggressive tumors, harboring a Ki-67 (MIB-1) staining index of 3% or more, and positive immunohistochemical staining for p53 protein, according to the World Health Organization (WHO) classification in 2004." | 2.50 | Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. ( Hirohata, T; Ishii, Y; Matsuno, A, 2014) |
| "A significant proportion of pituitary adenomas and carcinomas had low MGMT immunoexpression." | 2.47 | Treatment of pituitary neoplasms with temozolomide: a review. ( Cusimano, M; Gonzalez, R; Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Ortiz, LD; Scheithauer, BW; Syro, LV; Uribe, H, 2011) |
| "Temozolomide has recently been used for atypical adenomas or pituitary carcinomas." | 2.45 | [Recent trends in the pathophysiology and treatment of pituitary adenomas]. ( Matsuno, A, 2009) |
| "The majority of anterior pituitary tumors behave benignly, that is, they grow slowly and do not metastasize, and were therefore called adenomas." | 1.91 | Aggressive pituitary tumors (PitNETs). ( Nishioka, H, 2023) |
| "Pituitary carcinomas are thus clinically defined by the presence of craniospinal or distant metastases, typically developing several years after the first presentation." | 1.91 | [Aggressive pituitary adenoma and pituitary carcinoma]. ( Tóth, M, 2023) |
| "Temozolomide treatment in 156/171 patients resulted in complete response in 9." | 1.72 | Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. ( Burman, P; Dekkers, OM; Losa, M; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Theodoropoulou, M; Trouillas, J, 2022) |
| "Temozolomide therapy was initiated after surveillance MRI showed recurrence at 16 months postoperatively." | 1.72 | Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report. ( Bhabhra, R; Forbes, JA; Golnik, K; Hagen, M; Lin, AL; Mahammedi, A; Manzoor, S; Pater, L; Rothman, Y; Sengupta, S; Shah, S, 2022) |
| "Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal multimodality therapy." | 1.62 | Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. ( Ahuja, CK; Bhansali, A; Das, L; Dhandapani, S; Dutta, P; Gupta, K; Gupta, N; Radotra, BD; Rai, A; Sood, R; Sreedharanunni, S; Tripathi, M; Vaiphei, K; Walia, R, 2021) |
| "Although pituitary adenomas are considered benign lesions, a small group may show clinically aggressive behavior, sometimes independently from the classic markers of aggressiveness, including the Ki67 labeling index or p53 expression." | 1.46 | Aggressive Pituitary Adenomas: The Dark Side of the Moon. ( Abbritti, RV; Angileri, FF; Baldari, S; Barresi, V; Cannavò, S; Conti, A; Esposito, F; Ferraù, F; Germanò, A; Priola, SM; Tomasello, F, 2017) |
| "A 54-year-old man was diagnosed with Cushing's disease five years earlier on the basis of a typical clinical picture and hormonal tests." | 1.43 | Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment. ( Denew, P; Kurowska, M; Maksymowicz, M; Malicka, J; Tarach, JS; Zieliński, G, 2016) |
| "Only pituitary tumors with cerebrospinal and/or systemic metastasis are considered malignant carcinomas." | 1.43 | Refractory pituitary adenoma: a novel classification for pituitary tumors. ( Bao, X; Dai, C; Deng, K; Feng, M; Lian, W; Liu, X; Ma, S; Ma, W; Sun, B; Wang, R; Wang, Y; Xing, B; Yao, Y; Zhong, D, 2016) |
| "Pituitary adenomas are the commonest intracranial tumor, but metastases are rare (0." | 1.43 | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. ( Arnal, AV; Donovan, LE; Odia, Y; Wang, SH, 2016) |
| "Temozolomide (TMZ) is an oral alkylating agent that has been used over the past 8 years to treat aggressive pituitary tumors resistant to conventional therapy." | 1.43 | Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment. ( Aller, J; Campderá, M; Estrada, J; Lilienfeld, H; Magallón, R; Martín, P; Palacios, N; Saucedo, G, 2016) |
| "Temozolomide (TMZ) is an oral alkylating drug with good tolerability, approved for treatment of malignant gliomas." | 1.42 | Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. ( Andersen, M; Bengtsson, D; Berinder, K; Burman, P; Feldt Rasmussen, U; Hoybye, C; Johannsson, G; Maiter, D; Petersson, M; Ragnarsson, O; Rasmussen, ÅK; Schrøder, HD; van der Lely, AJ, 2015) |
| "Aggressive pituitary adenomas (PAs) are clinically challenging for endocrinologists and neurosurgeons due to their locally invasive nature and resistance to standard treatment (surgery, medical or radiotherapy)." | 1.42 | Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. ( Bertorelle, R; Boscaro, M; Ceccato, F; D'Avella, D; Denaro, L; Emanuelli, E; Gardiman, MP; Lombardi, G; Manara, R; Milanese, L; Occhi, G; Scanarini, M; Scaroni, C; Zagonel, V, 2015) |
| "We developed a mouse model of Lynch syndrome (Lgr5-CreERT2;Msh2(flox/-) mice) and found that environmental factors can modify the number and mutability of the MMR-deficient stem cells." | 1.40 | Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome. ( Cantelli, E; De Vries, S; Dekker, M; Delzenne-Goette, E; Plug, M; Song, JY; Te Riele, H; Van Der Wal, A; Van Gerwen, B; Wojciechowicz, K, 2014) |
| "Pituitary carcinoma is extremely rare and difficult to diagnose early." | 1.40 | Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management. ( Jiang, S; Yin, S; Zhong, C; Zhou, P, 2014) |
| "Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas." | 1.39 | DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. ( Amano, K; Arita, K; Asano, K; Fujio, S; Fukuhara, N; Hirohata, T; Hizuka, N; Ikeda, H; Ishii, Y; Isozaki, O; Iwai, Y; Kawamata, T; Matsuno, A; Nishioka, H; Ogawa, Y; Osamura, RY; Sakata, K; Shimatsu, A; Tahara, S; Takano, K; Takano, S; Teramoto, A; Tominaga, A; Yamada, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (4.29) | 29.6817 |
| 2010's | 52 (74.29) | 24.3611 |
| 2020's | 15 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Mirallas, O | 1 |
| Filippi-Arriaga, F | 1 |
| Hernandez Hernandez, I | 1 |
| Aubanell, A | 1 |
| Chaachou, A | 1 |
| Garcia-Alvarez, A | 1 |
| Hernando, J | 1 |
| Martínez-Saez, E | 1 |
| Biagetti, B | 1 |
| Capdevila, J | 1 |
| Das, L | 1 |
| Gupta, N | 1 |
| Dutta, P | 2 |
| Walia, R | 1 |
| Vaiphei, K | 1 |
| Rai, A | 2 |
| Radotra, BD | 2 |
| Gupta, K | 1 |
| Sreedharanunni, S | 1 |
| Ahuja, CK | 1 |
| Bhansali, A | 2 |
| Tripathi, M | 1 |
| Sood, R | 1 |
| Dhandapani, S | 1 |
| Shah, S | 1 |
| Manzoor, S | 1 |
| Rothman, Y | 1 |
| Hagen, M | 1 |
| Pater, L | 1 |
| Golnik, K | 1 |
| Mahammedi, A | 1 |
| Lin, AL | 2 |
| Bhabhra, R | 1 |
| Forbes, JA | 1 |
| Sengupta, S | 1 |
| Demarchi, G | 1 |
| Perrone, S | 1 |
| Esper Romero, G | 1 |
| De Bonis, C | 1 |
| Casasco, JP | 1 |
| Sevlever, G | 1 |
| Berner, SI | 1 |
| Cristina, C | 1 |
| Lasolle, H | 1 |
| Vasiljevic, A | 1 |
| Jouanneau, E | 2 |
| Ilie, MD | 1 |
| Raverot, G | 4 |
| Burman, P | 3 |
| Trouillas, J | 3 |
| Losa, M | 4 |
| McCormack, A | 4 |
| Petersenn, S | 3 |
| Popovic, V | 2 |
| Theodoropoulou, M | 1 |
| Dekkers, OM | 2 |
| Du Four, S | 1 |
| Van Der Veken, J | 1 |
| Duerinck, J | 1 |
| Vermeulen, E | 1 |
| Andreescu, CE | 1 |
| Bruneau, M | 1 |
| Neyns, B | 1 |
| Velthoven, V | 1 |
| Velkeniers, B | 1 |
| Kolitz, T | 1 |
| Greenman, Y | 2 |
| Nishioka, H | 2 |
| Padovan, M | 1 |
| Cerretti, G | 1 |
| Caccese, M | 1 |
| Barbot, M | 2 |
| Bergo, E | 1 |
| Occhi, G | 2 |
| Scaroni, C | 4 |
| Lombardi, G | 4 |
| Ceccato, F | 4 |
| Geer, EB | 1 |
| Tóth, M | 1 |
| Elbelt, U | 1 |
| Schlaffer, SM | 1 |
| Buchfelder, M | 1 |
| Knappe, UJ | 1 |
| Vila, G | 1 |
| Micko, A | 1 |
| Deutschbein, T | 1 |
| Unger, N | 1 |
| Lammert, A | 1 |
| Topuzoglu-Müller, T | 1 |
| Bojunga, J | 1 |
| Droste, M | 1 |
| Johanssen, S | 1 |
| Kolenda, H | 1 |
| Ritzel, K | 1 |
| Buslei, R | 1 |
| Strasburger, CJ | 1 |
| Honegger, J | 1 |
| Lizzul, L | 1 |
| Gardiman, MP | 2 |
| Regazzo, D | 1 |
| Bellu, L | 1 |
| Mazza, E | 3 |
| Yamamoto, M | 2 |
| Nakao, T | 1 |
| Ogawa, W | 1 |
| Fukuoka, H | 1 |
| Lenders, N | 1 |
| Gilis-Januszewska, A | 1 |
| Wilusz, M | 1 |
| Pantofliński, J | 1 |
| Turek-Jabrocka, R | 1 |
| Sokołowski, G | 1 |
| Sowa-Staszczak, A | 1 |
| Kluczyński, Ł | 1 |
| Pach, D | 1 |
| Zieliński, G | 2 |
| Hubalewska-Dydejczyk, A | 1 |
| Even-Zohar, N | 1 |
| Feelders, RA | 1 |
| Newell-Price, J | 1 |
| Pivonello, R | 1 |
| Nieman, LK | 1 |
| Hofland, LJ | 2 |
| Lacroix, A | 1 |
| Reddy, KS | 1 |
| Madugundu, AK | 1 |
| Solanki, HS | 1 |
| Kumar, N | 1 |
| Collier, D | 1 |
| Iacovazzo, D | 2 |
| Gupta, P | 1 |
| Raja, R | 1 |
| Gowda, H | 1 |
| Pandey, A | 1 |
| Devgun, JS | 1 |
| Korbonits, M | 1 |
| Tanaka, S | 1 |
| Morita, M | 1 |
| Takeno, A | 1 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Yamada, S | 3 |
| Inoshita, N | 1 |
| Oki, Y | 1 |
| Kurosaki, M | 1 |
| Sugimoto, T | 1 |
| Aharon-Hananel, G | 1 |
| Percik, R | 1 |
| Badarna, M | 1 |
| Uri, I | 1 |
| Tirosh, A | 1 |
| Matsuno, A | 4 |
| Murakami, M | 1 |
| Hoya, K | 1 |
| Yamada, SM | 1 |
| Miyamoto, S | 1 |
| Son, JH | 1 |
| Nishido, H | 1 |
| Ide, F | 1 |
| Nagashima, H | 1 |
| Sugaya, M | 1 |
| Hirohata, T | 3 |
| Mizutani, A | 1 |
| Okinaga, H | 1 |
| Ishii, Y | 3 |
| Tahara, S | 2 |
| Teramoto, A | 2 |
| Osamura, RY | 2 |
| Zacharia, BE | 1 |
| Gulati, AP | 1 |
| Bruce, JN | 2 |
| Carminucci, AS | 1 |
| Wardlaw, SL | 1 |
| Siegelin, M | 1 |
| Remotti, H | 1 |
| Lignelli, A | 1 |
| Fine, RL | 2 |
| Di Ieva, A | 2 |
| Rotondo, F | 5 |
| Syro, LV | 7 |
| Cusimano, MD | 3 |
| Kovacs, K | 11 |
| Mendola, M | 1 |
| Passeri, E | 1 |
| Ambrosi, B | 1 |
| Corbetta, S | 1 |
| Wang, Y | 2 |
| Li, J | 1 |
| Tohti, M | 1 |
| Hu, Y | 1 |
| Wang, S | 1 |
| Li, W | 1 |
| Lu, Z | 1 |
| Ma, C | 1 |
| Wojciechowicz, K | 1 |
| Cantelli, E | 1 |
| Van Gerwen, B | 1 |
| Plug, M | 1 |
| Van Der Wal, A | 1 |
| Delzenne-Goette, E | 1 |
| Song, JY | 1 |
| De Vries, S | 1 |
| Dekker, M | 1 |
| Te Riele, H | 1 |
| Zhong, C | 1 |
| Yin, S | 1 |
| Zhou, P | 1 |
| Jiang, S | 1 |
| Manara, R | 1 |
| Emanuelli, E | 1 |
| Denaro, L | 1 |
| Milanese, L | 1 |
| Bertorelle, R | 1 |
| Scanarini, M | 1 |
| D'Avella, D | 1 |
| Boscaro, M | 1 |
| Zagonel, V | 1 |
| Bruno, OD | 1 |
| Juárez-Allen, L | 1 |
| Christiansen, SB | 1 |
| Danilowicz, K | 1 |
| Strowd, RE | 1 |
| Salvatori, R | 1 |
| Laterra, JJ | 1 |
| Bengtsson, D | 1 |
| Schrøder, HD | 1 |
| Andersen, M | 1 |
| Maiter, D | 1 |
| Berinder, K | 1 |
| Feldt Rasmussen, U | 1 |
| Rasmussen, ÅK | 1 |
| Johannsson, G | 1 |
| Hoybye, C | 1 |
| van der Lely, AJ | 1 |
| Petersson, M | 1 |
| Ragnarsson, O | 1 |
| Ghazi, AA | 1 |
| Amirbaigloo, A | 1 |
| Fathalla, H | 1 |
| Liu, JK | 1 |
| Patel, J | 1 |
| Eloy, JA | 1 |
| Zhao, Y | 1 |
| Xiao, Z | 1 |
| Chen, W | 1 |
| Yang, J | 1 |
| Li, T | 1 |
| Fan, B | 1 |
| Campderá, M | 1 |
| Palacios, N | 1 |
| Aller, J | 1 |
| Magallón, R | 1 |
| Martín, P | 1 |
| Saucedo, G | 1 |
| Lilienfeld, H | 1 |
| Estrada, J | 1 |
| Bogazzi, F | 1 |
| Cannavo, S | 3 |
| Curtò, L | 2 |
| De Marinis, L | 1 |
| Mantovani, G | 1 |
| Minniti, G | 1 |
| Nizzoli, M | 1 |
| Reni, M | 2 |
| Kun, Z | 1 |
| Yuling, Y | 1 |
| Dongchun, W | 1 |
| Bingbing, X | 1 |
| Xiaoli, L | 1 |
| Bin, X | 1 |
| Kamiya-Matsuoka, C | 1 |
| Cachia, D | 1 |
| Waguespack, SG | 1 |
| Crane, CH | 1 |
| Mahajan, A | 1 |
| Brown, PD | 1 |
| Nam, JY | 1 |
| McCutcheon, IE | 1 |
| Penas-Prado, M | 1 |
| Sum, MW | 1 |
| DeAngelis, LM | 1 |
| Donovan, LE | 1 |
| Arnal, AV | 1 |
| Wang, SH | 1 |
| Odia, Y | 1 |
| Priola, SM | 1 |
| Esposito, F | 1 |
| Conti, A | 1 |
| Abbritti, RV | 1 |
| Barresi, V | 1 |
| Baldari, S | 1 |
| Ferraù, F | 2 |
| Germanò, A | 1 |
| Tomasello, F | 1 |
| Angileri, FF | 1 |
| Kurowska, M | 1 |
| Tarach, JS | 1 |
| Malicka, J | 1 |
| Maksymowicz, M | 1 |
| Denew, P | 1 |
| Dai, C | 3 |
| Feng, M | 3 |
| Liu, X | 3 |
| Ma, S | 3 |
| Sun, B | 1 |
| Bao, X | 3 |
| Yao, Y | 3 |
| Deng, K | 1 |
| Xing, B | 2 |
| Lian, W | 2 |
| Zhong, D | 1 |
| Ma, W | 3 |
| Wang, R | 3 |
| Widhalm, G | 1 |
| Wolfsberger, S | 1 |
| Preusser, M | 1 |
| Woehrer, A | 1 |
| Kotter, MR | 1 |
| Czech, T | 1 |
| Marosi, C | 1 |
| Knosp, E | 1 |
| Mohammed, S | 1 |
| Mason, W | 1 |
| Smyth, H | 1 |
| Thearle, MS | 1 |
| Freda, PU | 1 |
| Isaacson, SR | 1 |
| Lee, Y | 1 |
| Alameda Hernando, C | 1 |
| Lahera Vargas, M | 1 |
| Varela Da Costa, C | 1 |
| Fealey, ME | 1 |
| Scheithauer, BW | 7 |
| Horvath, E | 7 |
| Erickson, D | 2 |
| McLendon, R | 1 |
| Lloyd, RV | 2 |
| Dobson, M | 1 |
| Del Porto, L | 1 |
| Maartens, NF | 1 |
| Ortiz, LD | 4 |
| Lloyd, R | 1 |
| Lau, Q | 2 |
| Gonzalez, R | 1 |
| Uribe, H | 4 |
| Cusimano, M | 1 |
| Terreni, MR | 1 |
| Gill, AJ | 1 |
| Motta, M | 1 |
| Cangi, MG | 1 |
| Talarico, A | 1 |
| Mortini, P | 1 |
| Torre, ML | 1 |
| Pitini, V | 1 |
| Altavilla, G | 1 |
| Granata, F | 1 |
| Longo, M | 1 |
| Trimarchi, F | 1 |
| Salehi, F | 2 |
| Moyes, VJ | 1 |
| Drake, WM | 1 |
| Manoranjan, B | 1 |
| Sharma, S | 1 |
| Kros, JM | 1 |
| Fealey, M | 1 |
| McCormack, AI | 1 |
| Wass, JA | 1 |
| Grossman, AB | 1 |
| Hueng, DY | 1 |
| Ma, HI | 1 |
| Sytwu, HK | 1 |
| Liu, MY | 1 |
| Cai, F | 2 |
| Wei, J | 1 |
| Zhang, B | 2 |
| Li, G | 2 |
| Zuhur, SS | 1 |
| Tanik, C | 1 |
| Karaman, Ö | 1 |
| Velet, S | 1 |
| Çil, E | 1 |
| Öztürk, FY | 1 |
| Özkayalar, H | 1 |
| Müslüman, AM | 1 |
| Altuntaş, Y | 1 |
| Ersen, A | 2 |
| Fadul, CE | 2 |
| Annamalai, AK | 1 |
| Dean, AF | 1 |
| Kandasamy, N | 1 |
| Burton, H | 1 |
| Halsall, DJ | 1 |
| Shaw, AS | 1 |
| Antoun, NM | 1 |
| Cheow, HK | 1 |
| Kirollos, RW | 1 |
| Pickard, JD | 1 |
| Simpson, HL | 1 |
| Jefferies, SJ | 1 |
| Burnet, NG | 1 |
| Gurnell, M | 1 |
| Penagos, L | 1 |
| Asano, K | 1 |
| Ogawa, Y | 1 |
| Takano, S | 1 |
| Amano, K | 1 |
| Isozaki, O | 1 |
| Iwai, Y | 1 |
| Sakata, K | 1 |
| Fukuhara, N | 1 |
| Fujio, S | 1 |
| Arita, K | 1 |
| Takano, K | 1 |
| Tominaga, A | 1 |
| Hizuka, N | 1 |
| Ikeda, H | 1 |
| Kawamata, T | 1 |
| Shimatsu, A | 1 |
| Yang, Y | 1 |
| Wang, J | 1 |
| Guo, K | 1 |
| Xiao, J | 1 |
| Zhang, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism[NCT05255900] | 20 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for temozolomide and Adenoma
| Article | Year |
|---|---|
Aggressive corticotroph tumors and carcinomas.
Topics: Adenoma; Carcinoma; Corticotrophs; Humans; Pituitary Neoplasms; Temozolomide | 2022 |
Pituitary carcinoma - case series and review of the literature.
Topics: Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Humans; Pituitary Neoplasms | 2022 |
Refractory nonfunctioning pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Tem | 2023 |
Medical therapy for refractory pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma | 2020 |
Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Carcinoma; Dopamine Agonists | 2021 |
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Topics: Adenoma; Animals; Cell Transformation, Neoplastic; Dacarbazine; Humans; Pituitary Neoplasms; Temozol | 2018 |
Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Out | 2018 |
Management of NFAs: medical treatment.
Topics: Adenoma; Dacarbazine; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Temozolomide | 2018 |
Advances in the medical treatment of Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodi | 2019 |
Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; DNA-Binding Proteins; Hu | 2014 |
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents, Alkyl | 2014 |
Aggressive pituitary adenomas--diagnosis and emerging treatments.
Topics: Adenoma; Biomarkers, Tumor; Dacarbazine; Humans; Ki-67 Antigen; Neoplasm Invasiveness; Neovasculariz | 2014 |
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Topics: Adenoma; Administration, Oral; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; C | 2014 |
Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Asymptomatic Diseases; Dacarbazine; Growth Hormon | 2015 |
The role of temozolomide in the treatment of aggressive pituitary tumors.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Disease Progression; DN | 2015 |
Is there a role for early chemotherapy in the management of pituitary adenomas?
Topics: Adenoma; Antineoplastic Agents; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2016 |
[Recent trends in the pathophysiology and treatment of pituitary adenomas].
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines | 2009 |
[Treatment of clinically nonfunctioning pituitary adenomas].
Topics: Adenoma; Adult; Cranial Irradiation; Dacarbazine; Decompression, Surgical; Dopamine Agonists; Female | 2010 |
Treatment of pituitary neoplasms with temozolomide: a review.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinoma; Dacarbazine; DNA Modificat | 2011 |
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; | 2010 |
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dru | 2012 |
Temozolomide in aggressive pituitary adenomas and carcinomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Tem | 2012 |
1 trial available for temozolomide and Adenoma
| Article | Year |
|---|---|
O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Mod | 2009 |
45 other studies available for temozolomide and Adenoma
| Article | Year |
|---|---|
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Male; Middle Aged; Ne | 2021 |
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Topics: Adenoma; Adult; Cohort Studies; Early Medical Intervention; Female; Humans; India; Male; Middle Aged | 2021 |
Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.
Topics: Adenoma; DNA Mismatch Repair; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Pituitary Neo | 2022 |
Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.
Topics: Adenoma; Adrenocorticotropic Hormone; beta Catenin; Corticotrophs; Humans; Pituitary Neoplasms; Temo | 2022 |
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
Topics: Adenoma; Adrenocorticotropic Hormone; Bevacizumab; Carcinoma; Female; Humans; Immune Checkpoint Inhi | 2022 |
Aggressive pituitary tumors (PitNETs).
Topics: Adenoma; Carcinoma; Humans; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2023 |
[Aggressive pituitary adenoma and pituitary carcinoma].
Topics: Adenoma; Bevacizumab; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Temozolomide | 2023 |
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Female; Germany; Humans; Male; Middle | 2020 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2018 |
Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child.
Topics: Adenoma; Antineoplastic Protocols; Bevacizumab; Child, Preschool; Combined Modality Therapy; Human G | 2019 |
Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Combined Modality Therapy; D | 2019 |
Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.
Topics: Adenoma; Aged; Antineoplastic Agents, Alkylating; Carcinoma; Female; Humans; Israel; Male; Middle Ag | 2019 |
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ca | 2014 |
Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cereb | 2014 |
The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy.
Topics: Adenoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Blotting, Western; Dacarbazine; DNA Modific | 2014 |
Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Topics: Adenocarcinoma; Adenoma; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Colorectal Ne | 2014 |
Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
Topics: Adenocarcinoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Pitu | 2014 |
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Fem | 2015 |
Long-lasting complete remission after therapy with temozolomide in two patients with macrocorticotropinoma causing Cushing's disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Fe | 2015 |
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; | 2016 |
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Bi | 2015 |
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Topics: AC133 Antigen; Acetaldehyde Dehydrogenase Inhibitors; Adenoma; Animals; Antigens, CD; Antineoplastic | 2015 |
Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Chemotherapy, A | 2016 |
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow | 2016 |
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
Topics: Adenoma; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Hypoxi | 2016 |
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoradiotherapy; Dacarbaz | 2016 |
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; B | 2016 |
Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow-Up Studies; Humans; Image Pr | 2017 |
Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Dacarbazine; Humans; Male; Middle Aged; Pituitary ACTH Hy | 2016 |
Refractory pituitary adenoma: a novel classification for pituitary tumors.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Cell Proliferation; Dacarbazine; Di | 2016 |
Use of temozolomide in aggressive pituitary tumors: case report.
Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Cushing Syndrome; Dacarbazine; Female; Humans; Ma | 2009 |
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitab | 2011 |
MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents; Biomarkers, Tumor; Dacarbazine; DNA Methylation; | 2010 |
Comment on "Non-surgical treatment of hormone-secreting pituitary tumors".
Topics: Adenoma; Clinical Trials as Topic; Dacarbazine; Humans; Pituitary ACTH Hypersecretion; Pituitary Neo | 2010 |
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Female; Humans; Male; Middle Age | 2010 |
Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA | 2010 |
MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; DNA Methylati | 2011 |
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinosarcoma; Dacarbazine; Humans; | 2011 |
Temozolomide and pituitary adenoma.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Humans; | 2011 |
Effect of temozolomide on cell viability in gonadotroph adenoma cell lines.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Caspases; Cell Cycle; Cell Line, Tum | 2011 |
MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Cell Nucleus; Dacarbazine; DNA Modification | 2011 |
Anti-VEGF therapy in pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, H | 2012 |
Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Data Collection; DNA Modificat | 2013 |
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation | 2013 |